PMC6040243_01
(a) Rash after initiation of olaparib therapy. (b) Recurrence of rash after the second course of treatment with olaparib. (c) Third recurrence of rash after reinitiation of olaparib.
CRIONM2018-9529821.001.jpg
PMC6040243_01_CRIONM2018-9529821.001.jpg
fig1
Her physical examination revealed multiple erythematous nodules over the bilateral distal lower extremities which were markedly tender to palpation, along with trace edema in her bilateral lower extremities (Figure 1(a)). The first day she took the 300 mg BID dose, the patient developed recurrence of her erythema nodosum, and she was started on a course of prednisone with a resolution of her symptoms (Figure 1(b)). The patient was then restarted on olaparib at a reduced dose of 250 mg twice daily, but afterwards developed erythema nodosum again (Figure 1(c)).